Page last updated: 2024-12-04

befunolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Befunolol is a non-selective beta-blocker used to treat hypertension. It has been shown to be effective in lowering blood pressure by blocking the effects of adrenaline and noradrenaline on the heart and blood vessels. The compound is typically administered orally and has a relatively long duration of action. Research has shown that befunolol may also have anti-arrhythmic and anti-anginal properties. While its use has declined in recent years due to the availability of newer, more selective beta-blockers, research continues to explore potential applications for befunolol in areas such as glaucoma and migraine treatment. The compound is particularly interesting because it appears to have a unique mechanism of action that may offer benefits over other beta-blockers.'

befunolol: synonym BFE 60 refers to HCl; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2309
CHEMBL ID153984
CHEBI ID135212
SCHEMBL ID78720
MeSH IDM0048036

Synonyms (36)

Synonym
befunolol hydrochloride
befunolol
7-(2-hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl ketone
befunolol [inn]
befunololum [inn-latin]
brn 3620832
ethanone, 1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)-
ketone, 7-(2-hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl
2-acetyl-7-(2-hyroxy-3-isopropylaminopropoxy)benzofuran
1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)ethanone
D07496
befunolol (inn)
39552-01-7
CHEBI:135212
CHEMBL153984
1-[7-[2-hydroxy-3-(propan-2-ylamino)propoxy]-1-benzofuran-2-yl]ethanone
befunololum
418546mt3a ,
unii-418546mt3a
SCHEMBL78720
2-acetyl-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran
befunolol [who-dd]
befunolol [mi]
ZPQPDBIHYCBNIG-UHFFFAOYSA-N
DB09013
HY-101752
CS-6588
( inverted exclamation marka)-befunolol
Q4880388
DTXSID80865957
1-(7-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-1-benzofuran-2-yl)ethan-1-one
(+/-)-befunolol
NCGC00522022-01
()-befunolol
(??)-befunolol
AKOS040740969

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A significant increase in IOP was noted 15 min and 1 hr after a single dosing of caffeine alone."( Relationship between caffeine-induced ocular hypertension and ultrastructure changes of non-pigmented ciliary epithelial cells in rats.
Ando, T; Kurata, K; Maeda, M; Nishida, E; Suzuki, T; Tokuriki, M; Tsukuda, R, 1997
)
0.3
"In order to investigate the possible mechanisms for caffeine-induced ocular hypertension, the intraocular pressure (IOP) and the outflow through the trabecular meshwork were measured in beagle dog eyes after dosing with intravenous caffeine (30 mg/kg) alone or in combination with the topical beta-blocker befunolol [applied as 100 microliters of a 1% (w/v) solution] which inhibits aqueous humor formation in the ciliary body."( Aqueous humor dynamics in beagle dogs with caffeine-induced ocular hypertension.
Ando, T; Fujimoto, H; Kurata, K; Suzuki, T; Tokuriki, M; Tsukuda, R, 1998
)
0.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzofurans
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-199060 (63.16)18.7374
1990's23 (24.21)18.2507
2000's6 (6.32)29.6817
2010's2 (2.11)24.3611
2020's4 (4.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.12 (24.57)
Research Supply Index4.70 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (5.83%)5.53%
Reviews0 (0.00%)6.00%
Case Studies7 (6.80%)4.05%
Observational0 (0.00%)0.25%
Other90 (87.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]